# Beyond Clinical Trials: Experience with Bimekizumab in 3 Challenging Cases of Psoriatic Arthritis

## TL;DR

This paper presents three real-world cases where bimekizumab effectively treated challenging psoriatic arthritis patients who did not respond to other therapies.

## Contribution

The novelty lies in demonstrating bimekizumab's efficacy in complex, real-world PsA cases with comorbidities or prior treatment failures.

## Key findings

- Bimekizumab achieved remission in a patient with axial PsA who was intolerant to adalimumab.
- The drug provided rapid and sustained remission in a patient with severe psoriasis and obesity.
- Bimekizumab induced complete remission in a refractory PsA case with multiple comorbidities and failed therapies.

## Abstract

Psoriatic arthritis (PsA) is a multi-domain inflammatory disease affecting skin, nails and the musculoskeletal system, often accompanied by comorbidities that complicate the management of patients. Although several biologic therapies have demonstrated efficacy, real world data for their use in difficult to manage PsA cases is limited. Bimekizumab, a dual interleukin-17A/F inhibitor, offers a promising option in such patients.

We report three challenging PsA cases treated effectively with bimekizumab. The first case involved a woman with isolated axial PsA presenting as inflammatory cervical pain, who achieved remission after intolerance to adalimumab. The second concerned a man with severe psoriasis and morbid obesity, who achieved rapid and sustained remission. The third case refers to a man with refractory PsA, multiple comorbidities and failure of several biologic and targeted therapies. Bimekizumab achieved complete remission of joint and skin manifestations in all three cases.

These real-world cases support the efficacy and tolerability of bimekizumab across diverse and complex PsA presentations. Dual IL-17A/F inhibition may provide a valuable therapeutic option for patients with refractory disease, comorbidities, or rare phenotypes.